New antibody drug stops aggressive prostate cancer from spreading
A fully human antibody has halted the growth and spread of aggressive prostate cancer in preclinical studies, offering a potential new therapeutic approach to prevent metastasis.
Researchers at Umeå University developed a fully human antibody that stopped both tumor growth and metastasis in an aggressive prostate cancer model. The drug works via a novel mechanism, potentially reducing side‑effect risks, and may represent a promising step toward a new, safer treatment for advanced prostate cancer. Further preclinical safety work and regulatory approval are required before clinical use.
This study introduces a novel therapeutic strategy that could curb metastatic spread in advanced prostate cancer, a leading cause of cancer‑related death, while possibly offering fewer adverse effects than current treatments.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience